Stoke Therapeutics, Inc. (STOK) — closed signal from January 28, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on April 28, 2026 — +10.9% at the close.
Predicted vs. what happened
What happened
Reached its target in 26 days.
The thesis — published January 28, 2026
Stoke is a small biotech that recently showed real progress: they are expanding facilities and gave clearer timelines for late-stage tests. That helped investors stay interested even though the stock fell. Trading is light and prices are still recovering, so this is a short-term, careful trade. If selling calms, the stock could bounce strongly within a few months.
Primary drivers
- Facility growth shows they are preparing to scale drug development and future sales
- Clearer late-stage test timing keeps attention on the main program
- Stock fell too far and could bounce if selling eases
- Adds healthcare exposure to reduce tech-heavy portfolio risk
How it played out
STOK: target reached in 26 days
Lyra published STOK on 2026-01-28 at 30.06 as a short-term healthcare signal. The thesis expected 20% growth. It pointed to facility growth, clearer late-stage test timing, a stock that had fallen too far, and the chance of a bounce if selling eased.
Inside the window from 2026-01-28 to 2026-04-28, STOK reached the 36.07 target in 26 days. It peaked at 40.22 on 2026-03-10, with a 33.8% gain at the peak. It ended the window at 33.33. The thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.